Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.153
Buy
RSI(14)
47.866
Neutral
STOCH(KDJ)(9,3,3)
51.955
Sell
ATR(14)
1.795
High Vlolatility
CCI(14)
-55.858
Neutral
Williams %R
73.494
Sell
TRIX(12,20)
0.120
Sell
StochRSI(14)
0.000
Sell
Boston Scientific Corp
BSX104.230USD
-1.001-0.95%
Market hours （ET）Quotes delayed by 15 min
154.30BMarket Cap
61.59P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated：2025-09-10Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
36
analysts
Buy
Current Rating
123.771
Target Price
+17.62%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. It also owns the transcarotid artery revascularization (TCAR) platform.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.05% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 188.63.
Undervalued
The company’s latest PE is 62.01, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.39B shares, increasing 0.01% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 136.47M shares of this stock.
Financial Health
Currency: USD Updated：2025-09-10The company's current financial score is 7.01, which is lower than the Healthcare Equipment & Supplies industry's average of 7.15. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 4.66B, representing a year-over-year increase of 20.93%, while its net profit experienced a year-over-year increase of 36.16%.
Score
Financials
6.46
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.08
Operational Efficiency
7.49
Growth Potential
6.93
Shareholder Returns
7.08
Company Valuation
Currency: USD Updated：2025-09-10The company’s current valuation score is 4.80, which is higher than the Healthcare Equipment & Supplies industry's average of 2.15. Its current P/E ratio is 62.39, which is 38.87% below the recent high of 86.64 and -2.05% above the recent low of 63.67.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 19/208
No Data
Earnings Forecast
Currency: USD Updated：2025-09-10The company’s current earnings forecast score is 8.56, which is higher than the Healthcare Equipment & Supplies industry's average of 7.66. The average price target for Boston Scientific Corp is 125.00, with a high of 140.00 and a low of 101.21.
Score
Support & Resistance
No Data
Analyst Rating
Based on
36
analysts
Buy
Current Rating
123.771
Target Price
+17.62%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
95
Total
4
Median
7
Average
Company name
Ratings
Analysts
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
34
Veeva Systems Inc
VEEV
32
Thermo Fisher Scientific Inc
TMO
31
Danaher Corp
DHR
26
1
2
3
...
19
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated：2025-09-10The company’s current price momentum score is 9.22, which is higher than the Healthcare Equipment & Supplies industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 108.05 and the support level at 102.64, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
107.194
Sell
MA10
106.728
Sell
MA20
105.641
Sell
MA50
104.872
Sell
MA100
103.784
Buy
MA200
100.410
Buy
Institutional Confidence
Currency: USD Updated：2025-09-10The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. The latest institutional shareholding proportion is 93.57%, representing a quarter-over-quarter decrease of 0.25%. The largest institutional shareholder is The Vanguard, holding a total of 136.47M shares, representing 9.21% of shares outstanding, with 2.64% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
BlackRock Institutional Trust Company, N.A.
State Street Global Advisors (US)
Wellington Management Company, LLP
Geode Capital Management, L.L.C.
Capital World Investors
Managed Account Advisors LLC
The Bollard Group, LLC
1
2
Risk Assessment
Currency: USD Updated：2025-09-10The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.63
VaR
+2.06%
240-Day Maximum Drawdown
+15.52%
240-Day Volatility
+27.52%
Return
Best Daily Return
60 days
+4.46%
120 days
+6.76%
5 years
+6.76%
Worst Daily Return
60 days
-2.45%
120 days
-8.93%
5 years
-8.93%
Sharpe Ratio
60 days
+1.99
120 days
+0.86
5 years
+1.20
Risk Assessment
Maximum Drawdown
240 days
+15.52%
3 years
+15.52%
5 years
+25.18%
Return-to-Drawdown Ratio
240 days
+1.85
3 years
+3.52
5 years
+1.76
Skewness
240 days
-0.72
3 years
-0.28
5 years
-0.16
Volatility
Realised Volatility
240 days
+27.52%
5 years
+24.65%
Standardised True Range
240 days
+1.90%
5 years
+1.10%
Downside Risk-Adjusted Return
120 days
+104.53%
240 days
+104.53%
Maximum Daily Upside Volatility
60 days
+14.08%
Maximum Daily Downside Volatility
60 days
+14.37%
Liquidity
Average Turnover Rate
60 days
+0.49%
120 days
+0.52%
5 years
--
Turnover Deviation
20 days
-11.06%
60 days
+8.05%
120 days
+14.61%
Peer Comparison
Currency: USD Updated：2025-09-10Boston Scientific Corp
BSX
6.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
PODD
7.89 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
STVN
7.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Penumbra Inc
PEN
7.34 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
iRhythm Technologies Inc
IRTC
7.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Merit Medical Systems Inc
MMSI
7.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
